| scholarly article | Q13442814 |
| P50 | author | Juthathip Mongkolsapaya | Q59593587 |
| Gavin R Screaton | Q42305839 | ||
| P2093 | author name string | Sophie Yacoub | |
| P2860 | cites work | Alteration of cytokines and chemokines during febrile episodes associated with endothelial cell damage and plasma leakage in dengue hemorrhagic fever | Q40276342 |
| Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement | Q40303277 | ||
| Dengue virus nonstructural protein NS1 binds to prothrombin/thrombin and inhibits prothrombin activation | Q40303865 | ||
| Anti-dengue virus nonstructural protein 1 antibodies recognize protein disulfide isomerase on platelets and inhibit platelet aggregation | Q40377239 | ||
| Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. | Q40469577 | ||
| Antibodies from dengue patient sera cross-react with endothelial cells and induce damage | Q40570751 | ||
| Endothelial cell apoptosis induced by antibodies against dengue virus nonstructural protein 1 via production of nitric oxide | Q40579380 | ||
| Failure of high-dose methylprednisolone in established dengue shock syndrome: a placebo-controlled, double-blind study. | Q40715480 | ||
| Predicting outcome from dengue | Q21146686 | ||
| Dengue virus infection in Africa | Q22305632 | ||
| The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus | Q22680660 | ||
| Aedes albopictus, an arbovirus vector: From the darkness to the light | Q24289424 | ||
| An in-depth analysis of original antigenic sin in dengue virus infection | Q24606493 | ||
| The global distribution and burden of dengue | Q24628768 | ||
| Global spread of dengue virus types: mapping the 70 year history | Q24736362 | ||
| Structure of dengue virus: implications for flavivirus organization, maturation, and fusion | Q24736810 | ||
| Climate change and dengue: a critical and systematic review of quantitative modelling approaches | Q26828601 | ||
| Secreted NS1 of Dengue Virus Attaches to the Surface of Cells via Interactions with Heparan Sulfate and Chondroitin Sulfate E | Q27481677 | ||
| High Pro-Inflammatory Cytokine Secretion and Loss of High Avidity Cross-Reactive Cytotoxic T-Cells during the Course of Secondary Dengue Virus Infection | Q27481682 | ||
| Immature Dengue Virus: A Veiled Pathogen? | Q27490592 | ||
| Serotype-Specific Differences in the Risk of Dengue Hemorrhagic Fever: An Analysis of Data Collected in Bangkok, Thailand from 1994 to 2006 | Q27491001 | ||
| Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses | Q27491299 | ||
| The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1 | Q27491317 | ||
| Structure of the dengue virus envelope protein after membrane fusion | Q27643009 | ||
| The flavivirus precursor membrane-envelope protein complex: structure and maturation | Q27650164 | ||
| Structure of the immature dengue virus at low pH primes proteolytic maturation | Q27650165 | ||
| Structural Analysis of a Dengue Cross-Reactive Antibody Complexed with Envelope Domain III Reveals the Molecular Basis of Cross-Reactivity | Q27678419 | ||
| The structural basis for serotype-specific neutralization of dengue virus by a human antibody | Q27681306 | ||
| A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface | Q27681319 | ||
| Flavivirus NS1 Structures Reveal Surfaces for Associations with Membranes and the Immune System | Q27681625 | ||
| Structural basis of Flavivirus NS1 assembly and antibody recognition | Q27681981 | ||
| Recognition determinants of broadly neutralizing human antibodies against dengue viruses | Q27697333 | ||
| Pathogenesis of dengue: challenges to molecular biology | Q27860978 | ||
| Cross-reacting antibodies enhance dengue virus infection in humans | Q28281588 | ||
| A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults | Q28475036 | ||
| Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1 | Q28943386 | ||
| Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission | Q29615114 | ||
| A Wolbachia symbiont in Aedes aegypti limits infection with dengue, Chikungunya, and Plasmodium | Q29616261 | ||
| Stable introduction of a life-shortening Wolbachia infection into the mosquito Aedes aegypti | Q29616268 | ||
| A structural perspective of the flavivirus life cycle | Q29616269 | ||
| Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate | Q29618060 | ||
| High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever | Q29618174 | ||
| Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever | Q29619585 | ||
| Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections | Q33342343 | ||
| Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection. | Q33378095 | ||
| Lack of efficacy of prophylactic platelet transfusion for severe thrombocytopenia in adults with acute uncomplicated dengue infection | Q33383747 | ||
| Kinetics of plasma viremia and soluble nonstructural protein 1 concentrations in dengue: differential effects according to serotype and immune status | Q33394239 | ||
| Clinical features of dengue in a large Vietnamese cohort: intrinsically lower platelet counts and greater risk for bleeding in adults than children | Q33402055 | ||
| Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial | Q33402687 | ||
| Protection against dengue virus infection in mice by administration of antibodies against modified nonstructural protein 1. | Q33414156 | ||
| Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial | Q33841045 | ||
| Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles | Q34046013 | ||
| Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. | Q34165624 | ||
| Association of mast cell-derived VEGF and proteases in Dengue shock syndrome | Q34171756 | ||
| Field performance of engineered male mosquitoes | Q34228593 | ||
| Diabetes with hypertension as risk factors for adult dengue hemorrhagic fever in a predominantly dengue serotype 2 epidemic: a case control study | Q34260245 | ||
| A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients | Q34288828 | ||
| A variant in the CD209 promoter is associated with severity of dengue disease | Q34412344 | ||
| Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial | Q34422058 | ||
| Epidemiological factors associated with dengue shock syndrome and mortality in hospitalized dengue patients in Ho Chi Minh City, Vietnam | Q34422217 | ||
| Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial | Q34428943 | ||
| Efficacy of a tetravalent dengue vaccine in children in Latin America. | Q34446032 | ||
| Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease | Q34487028 | ||
| Genetic variants of MICB and PLCE1 and associations with non-severe dengue | Q34639559 | ||
| The effect of virus-blocking Wolbachia on male competitiveness of the dengue vector mosquito, Aedes aegypti | Q34679915 | ||
| Sequential waves of gene expression in patients with clinically defined dengue illnesses reveal subtle disease phases and predict disease severity | Q34855189 | ||
| Secreted dengue virus nonstructural protein NS1 is an atypical barrel-shaped high-density lipoprotein | Q34977722 | ||
| Ongoing local transmission of dengue in Japan, August to September 2014. | Q35055396 | ||
| Adult survivorship of the dengue mosquito Aedes aegypti varies seasonally in central Vietnam. | Q35097794 | ||
| Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2 | Q35105926 | ||
| A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins | Q35138111 | ||
| Mechanotransduction and flow across the endothelial glycocalyx | Q35147509 | ||
| ??? | Q27006626 | ||
| An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques | Q35272502 | ||
| Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera | Q35294150 | ||
| A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus | Q35654743 | ||
| New dengue virus type 1 genotype in Colombo, Sri Lanka | Q35847184 | ||
| Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions | Q35982791 | ||
| Dengue vector control strategies in an urban setting: an economic modelling assessment | Q36132072 | ||
| Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults | Q36181531 | ||
| Variation in inflammatory/regulatory cytokines in secondary, tertiary, and quaternary challenges with dengue virus | Q36213311 | ||
| Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study | Q36288109 | ||
| DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers | Q36352752 | ||
| Association between magnitude of the virus-specific plasmablast response and disease severity in dengue patients | Q36487320 | ||
| Lovastatin for the Treatment of Adult Patients With Dengue: A Randomized, Double-Blind, Placebo-Controlled Trial | Q36497872 | ||
| Contributions of mast cells and vasoactive products, leukotrienes and chymase, to dengue virus-induced vascular leakage | Q36804428 | ||
| Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells | Q36895622 | ||
| High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection | Q37336440 | ||
| HLA and other gene associations with dengue disease severity | Q37608071 | ||
| The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease | Q37903445 | ||
| Animal models of dengue virus infection | Q37987131 | ||
| Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection | Q38087545 | ||
| Chikungunya and dengue autochthonous cases in Europe, 2007-2012. | Q38130346 | ||
| Susceptibility to dengue hemorrhagic fever in vietnam: evidence of an association with variation in the vitamin d receptor and Fc gamma receptor IIa genes. | Q38362309 | ||
| Dengue human infection models to advance dengue vaccine development | Q38386336 | ||
| Exploring the origin and potential for spread of the 2013 dengue outbreak in Luanda, Angola | Q38989452 | ||
| Dengue human infection models supporting drug development | Q39590469 | ||
| Statins reduce dengue virus production via decreased virion assembly | Q39598018 | ||
| Dengue Human Infection Models to Advance Dengue Vaccine Development | Q40133947 | ||
| Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity | Q40140011 | ||
| Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination | Q40140017 | ||
| Chloroquine interferes with dengue-2 virus replication in U937 cells | Q40208955 | ||
| The 2012 dengue outbreak in Madeira: exploring the origins | Q40215447 | ||
| A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates | Q40255696 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Dengue virus | Q476209 |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | F1000Research | Q27701587 |
| P1476 | title | Recent advances in understanding dengue | |
| P478 | volume | 5 |
| Q58596596 | A scorpion venom peptide Ev37 restricts viral late entry by alkalizing acidic organelles |
| Q41928846 | An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design |
| Q33609071 | Association of Endothelial Glycocalyx and Tight and Adherens Junctions With Severity of Plasma Leakage in Dengue Infection |
| Q38696035 | Blockade of dengue virus infection and viral cytotoxicity in neuronal cells in vitro and in vivo by targeting endocytic pathways |
| Q56481199 | Complete assembly of a dengue virus type 3 genome from a recent genotype III clade by metagenomic sequencing of serum |
| Q64360473 | Decoding the enigma of antiviral crisis: Does one target molecule regulate all? |
| Q41930015 | Dengue fever. Clinical features of 567 consecutive patients admitted to a tertiary care center in Saudi Arabia. |
| Q115234065 | Dengue virus NS1 protein conveys pro‐inflammatory signals by docking onto high‐density lipoproteins |
| Q57065813 | Dengue virus enters and exits epithelial cells through both apical and basolateral surfaces and perturbs the apical junctional complex |
| Q60303769 | Epidemiological profile of dengue in Zhejiang Province, southeast China |
| Q58794185 | Evaluation of Effectiveness of a Community-Based Intervention for Control of Dengue Virus Vector, Ouagadougou, Burkina Faso |
| Q47574097 | High prevalence of dengue antibodies and the arginine variant of the FcγRIIa polymorphism in asymptomatic individuals in a population of Minas Gerais State, Southeast Brazil |
| Q90185462 | Inhibitory Effect of Alpha-Mangostin to Dengue Virus Replication and Cytokines Expression in Human Peripheral Blood Mononuclear Cells |
| Q26700001 | MEPPitope: spatial, electrostatic and secondary structure perturbations in the post-fusion Dengue virus envelope protein highlights known epitopes and conserved residues in the Zika virus |
| Q92752380 | Molecular Epidemiology of Dengue in Panama: 25 Years of Circulation |
| Q57454669 | Nonalcoholic fatty liver disease is associated with increased hemoconcentration, thrombocytopenia, and longer hospital stay in dengue-infected patients with plasma leakage |
| Q89992595 | Paracetamol for dengue fever: no benefit and potential harm? |
| Q56339293 | The antiparasitic drug niclosamide inhibits dengue virus infection by interfering with endosomal acidification independent of mTOR |
| Q27010749 | Zika virus: An emergent neuropathological agent |
Search more.